Zacks: Brokerages Anticipate Celsion Co. (NASDAQ:CLSN) to Post -$1.01 EPS

Wall Street brokerages forecast that Celsion Co. (NASDAQ:CLSN – Get Rating) will report earnings per share of ($1.01) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Celsion’s earnings. The lowest EPS estimate is ($1.05) and the highest is ($0.96). Celsion reported earnings of ($1.35) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 25.2%. The business is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Celsion will report full year earnings of ($3.98) per share for the current fiscal year, with EPS estimates ranging from ($4.37) to ($3.52). For the next financial year, analysts anticipate that the firm will report earnings of ($4.18) per share, with EPS estimates ranging from ($4.50) to ($3.76). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Celsion.

A number of equities research analysts recently issued reports on CLSN shares. StockNews.com began coverage on Celsion in a research report on Wednesday. They set a “hold” rating on the stock. HC Wainwright assumed coverage on Celsion in a research report on Wednesday, April 13th. They issued a “buy” rating and a $16.00 price target on the stock.

Shares of CLSN traded down $0.03 during mid-day trading on Wednesday, hitting $2.99. 875 shares of the company’s stock were exchanged, compared to its average volume of 267,816. The company has a quick ratio of 7.67, a current ratio of 7.67 and a debt-to-equity ratio of 0.10. Celsion has a 52 week low of $3.00 and a 52 week high of $23.25. The stock’s 50-day simple moving average is $4.73 and its 200-day simple moving average is $8.15. The firm has a market cap of $17.26 million, a price-to-earnings ratio of -0.77 and a beta of 2.11.

Hedge funds have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in Celsion during the fourth quarter worth about $55,000. GSA Capital Partners LLP increased its position in Celsion by 435.2% during the 4th quarter. GSA Capital Partners LLP now owns 133,006 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 108,155 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Celsion during the 4th quarter worth approximately $59,000. FNY Investment Advisers LLC bought a new position in Celsion in the 4th quarter valued at approximately $35,000. Finally, Jane Street Group LLC boosted its position in Celsion by 181.8% in the third quarter. Jane Street Group LLC now owns 36,055 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 23,261 shares in the last quarter. 10.75% of the stock is currently owned by hedge funds and other institutional investors.

Celsion Company Profile (Get Rating)

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.

Recommended Stories